Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy

被引：10
作者：
Boglione, L. [1 ]
De Nicolo, A. [1 ]
Cardellino, C. S. [1 ]
Ruggiero, T. [1 ]
Ghisetti, V. [1 ]
Cariti, G. [1 ]
Di Perri, G. [1 ]
D'Avolio, A. [1 ]
机构：
[1] Univ Turin, Amedeo di Savoia Hosp, Dept Infect Dis, Cso Svizzera 164, Turin, Italy
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2015年 / 21卷 / 02期
关键词：
Boceprevir; breakthrough; HCV; resistance; triple therapy; CHRONIC HEPATITIS-C; PROTEASE INHIBITOR; RESISTANCE MUTATIONS; NAIVE PATIENTS; TELAPREVIR; RIBAVIRIN;
D O I：
10.1016/j.cmi.2014.07.009
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
In a prospective cohort of 18 patients treated with boceprevir, we examined the role of boceprevir plasma concentration at the onset of breakthrough during the treatment. Nine patients experienced breakthrough during therapy. The resistance patterns were as follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH 534128) median concentration in patients with breakthrough was 48.3 ng/mL (interquartile range 43-58 ng/mL); in others, it was significantly (p 0.019) higher: 151 ng/mL. Low boceprevir plasma concentration can lead to virologic resistance; therapeutic drug monitoring should be used to prevent the onset of viral breakthrough during triple-regimen therapy with boceprevir. Clinical Microbiology and Infection (C) 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：205.e1 / 205.e3
页数：3
相关论文
共 16 条
  • [1] Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies
    Barnard, Richard J. O.
    Howe, John A.
    Ogert, Robert A.
    Zeuzem, Stefan
    Poordad, Fred
    Gordon, Stuart C.
    Ralston, Robert
    Tong, Xiao
    Sniukiene, Vilma
    Strizki, Julie
    Ryan, Desmond
    Long, Jianmin
    Qiu, Ping
    Brass, Clifford A.
    Albrecht, Janice
    Burroughs, Margaret
    Vuocolo, Scott
    Hazuda, Daria J.
    [J]. VIROLOGY, 2013, 444 (1-2) : 329 - 336
  • [2] Chen KX, 2010, PROGR MED CHEM, V49, P1, DOI 10.1016/S0079-6468(10)49001-3
  • [3] Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients
    D'Avolio, A
    Ibañez, A
    Sciandra, M
    Siccardi, M
    de Requena, DG
    Bonora, S
    Di Perri, G
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 835 (1-2): : 127 - 130
  • [4] A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir
    D'Avolio, Antonio
    De Nicolo, Amedeo
    Agnesod, Danilo
    Simiele, Marco
    Abdi, Adnan Mohamed
    Penchala, Sujan Dilly
    Boglione, Lucio
    Cariti, Giuseppe
    Di Perri, Giovanni
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2013, 78-79 : 217 - 223
  • [5] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982
  • [6] SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)
    Hezode, C.
    Dorival, C.
    Zoulim, F.
    Poynard, T.
    Mathurin, P.
    Pol, S.
    Larrey, D.
    Cacoub, P.
    de Ledinghen, V.
    Bourliere, M.
    Bernard, P. H.
    Riachi, G.
    Alric, L.
    Samuel, D.
    Barthe, Y.
    Fontaine, H.
    Carrat, F.
    Bronowicki, J. -P.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S4 - S4
  • [7] Hepatitis C Viral Evolution in Genotype 1 Treatment-Naive and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
    Kieffer, Tara L.
    De Meyer, Sandra
    Bartels, Doug J.
    Sullivan, James C.
    Zhang, Eileen Z.
    Tigges, Ann
    Dierynck, Inge
    Spanks, Joan
    Dorrian, Jennifer
    Jiang, Min
    Adiwijaya, Bambang
    Ghys, Anne
    Beumont, Maria
    Kauffman, Robert S.
    Adda, Nathalie
    Jacobson, Ira M.
    Sherman, Kenneth E.
    Zeuzem, Stefan
    Kwong, Ann D.
    Picchio, Gaston
    [J]. PLOS ONE, 2012, 7 (04):
  • [8] Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients
    Kuntzen, Thomas
    Timm, Joerg
    Berical, Andrew
    Lennon, Niall
    Berlin, Aaron M.
    Young, Sarah K.
    Lee, Bongshin
    Heckerman, David
    Carlson, Jonathan
    Reyor, Laura L.
    Kleyman, Marianna
    McMahon, Cory M.
    Birch, Christopher
    Wiesch, Julian Schulze zur
    Ledlie, Timothy
    Koehrsen, Michael
    Kodira, Chinnappa
    Roberts, Andrew D.
    Lauer, Georg M.
    Rosen, Hugo R.
    Bihl, Florian
    Cerny, Andreas
    Spengler, Ulrich
    Liu, Zhimin
    Kim, Arthr Y.
    Xing, Yanming
    Schneidewind, Arne
    Madey, Margaret A.
    Fleckenstein, Jaquelyn F.
    Park, Vicki M.
    Galagan, James E.
    Nusbaum, Chad
    Walker, Bruce D.
    Lake-Bakaar, Gerond V.
    Daar, Eric S.
    Jacobson, Ira M.
    Gomperts, Edivard D.
    Edlin, Brian R.
    Donfield, Sharyne M.
    Chung, Raymond T.
    Talal, Andrew H.
    Marion, Tony
    Birren, Bruce W.
    Henn, Mattliew R.
    Allen, Todd M.
    [J]. HEPATOLOGY, 2008, 48 (06) : 1769 - 1778
  • [9] MOHD HK, 2013, HEPATOLOGY, V57, P1333, DOI DOI 10.1002/HEP.26141
  • [10] The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients
    Nelson, David R.
    [J]. LIVER INTERNATIONAL, 2011, 31 : 53 - 57
12